Scholarlink

Background <p>Hepatitis C virus (HCV) poses a major public health challenge in Egypt. Direct-acting antivirals (DAAs) are considered the optimal treatment for chronic HCV patients, given their high efficacy (sustained virologic response [SVR] &gt; 90%) and minimal side effects. However, data on the association between DAA use and hepatocellular carcinoma (HCC) development remain controversial.</p> Aim <p>To assess the long-term effects of different Sofosbuvir-based DAAs on chronic HCV patients with compensated cirrhosis.</p> Methods <p>This longitudinal cohort study included 424 chronic HCV patients with compensated cirrhosis who were eligible for antiviral therapy according to national guidelines. Baseline and follow-up laboratory tests and abdominal ultrasounds were conducted over a median follow up period of 200&#xa0;weeks.</p> Results <p>Follow-up showed significant improvements in transaminase levels, albumin, and alpha-fetoprotein (AFP), all with <i>P</i>-values &lt; 0.01, along with a decrease in hemoglobin levels (<i>P</i> &lt; 0.01). During follow-up, 39 patients (9.2%) developed HCC, all of whom had low albumin levels.</p> Conclusion <p>DAA treatment was not associated with a worsening biochemical profile. However, the occurrence of HCC in cirrhotic patients post-DAA treatment highlights the need for close monitoring and regular HCC screening after treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-term outcomes of treated chronic HCV compensated cirrhotic patients in Egypt

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月30日

查看全文
  • Omnia Tantawi,
  • Eman Elsayed,
  • Mohamed Abdallah,
  • Wafaa ElAkel,
  • Ahmed Fouad

摘要

Background

Hepatitis C virus (HCV) poses a major public health challenge in Egypt. Direct-acting antivirals (DAAs) are considered the optimal treatment for chronic HCV patients, given their high efficacy (sustained virologic response [SVR] > 90%) and minimal side effects. However, data on the association between DAA use and hepatocellular carcinoma (HCC) development remain controversial.

Aim

To assess the long-term effects of different Sofosbuvir-based DAAs on chronic HCV patients with compensated cirrhosis.

Methods

This longitudinal cohort study included 424 chronic HCV patients with compensated cirrhosis who were eligible for antiviral therapy according to national guidelines. Baseline and follow-up laboratory tests and abdominal ultrasounds were conducted over a median follow up period of 200 weeks.

Results

Follow-up showed significant improvements in transaminase levels, albumin, and alpha-fetoprotein (AFP), all with P-values < 0.01, along with a decrease in hemoglobin levels (P < 0.01). During follow-up, 39 patients (9.2%) developed HCC, all of whom had low albumin levels.

Conclusion

DAA treatment was not associated with a worsening biochemical profile. However, the occurrence of HCC in cirrhotic patients post-DAA treatment highlights the need for close monitoring and regular HCC screening after treatment.